Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Phase 1

Completed

• Conditions: Migraine
• Interventions: Drug: zolmitriptan; Drug: CVT-427 (zolmitriptan inhalation powder),

• Registration Number: NCT02609945
• Lead Sponsor: Acorda Therapeutics

Brief Summary

This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.

Detailed Description

Objectives:

* To evaluate the overall safety and tolerability of single, inhaled doses of CVT-427 (zolmitriptan inhalation powder) in healthy adults, with special emphasis on cardiopulmonary effects.

* To describe the pharmacokinetics (PK) of single, inhaled doses of CVT-427, Zomig® Tablet, and Zomig® Nasal Spray in healthy adults.

Study Timeline

• Study Start: 2015-11
• Study First Submitted: 2015-11-16
• Study First Submitted QC: 2015-11-18
• Study First Posted: 2015-11-20
• Primary Completion: 2015-12
• Study Completion: 2016-04
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-03
• Last Update Posted: 2016-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Healthy adult men or women volunteers aged 18 to 65 years, inclusive;
• Triptan-naïve;
• Body mass index (BMI) between 18 to 30 kg/m2;
• Forced expiratory volume in one second (FEV1) greater than 80% of predicted for race, age, sex, and height and FEV1/FVC (forced vital capacity) ratio greater than or equal to 70%;
• No history of asthma;
• Non-smoking for at least 5 years;
• In good general health with no clinically significant abnormalities or recognized cardiovascular risk factors that preclude use of triptans and that would interfere with participation in this study as determined by medical history, physical examination, electrocardiogram, and clinical laboratory test results; and negative tests for drug and alcohol, serology, and for pregnancy for female subjects of childbearing potential.

Exclusion Criteria

• Subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and who does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product;
• Any cardiovascular risk factor including clinically relevant ECG parameter (e.g., PR interval, QRS deviation) or other clinically significant ECG abnormality;
• History of asthma (including exercise-induced asthma and cold-induced asthma) or chronic obstructive pulmonary disorder (COPD) requiring intermittent or continuous use of any oral or inhaled medication therapy within last 3 years;
• Any flu-like syndrome or other respiratory infections within 4 weeks of CVT-427 administration;
• Unable to tolerate blood draws.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CVT-427 (zolmitriptan inhalation powder)	CVT-427 (zolmitriptan inhalation powder),	Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart. Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL.
CVT-427 (zolmitriptan inhalation powder)	zolmitriptan	Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart. Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL.

Primary Outcome Measures

Name	Time	Method
Number of patients with adverse events (AEs) including serious AEs	up to 23 days
Pulmonary function	within 90 min prior to dosing and at specified time points up to 24 hours post-dose	Measured by spirometry using the guideline specified by the Third National Health and Nutrition Examination Survey (NHANES III)
Maximum observed plasma drug concentration (Cmax)	within 15 minutes pre-dose and at specified time points up to 24 hours post-dose
Time to maximum observed plasma drug concentration (Tmax)	within 15 minutes pre-dose and at specified time points up to 24 hours post-dose
Area under the concentration time curve (AUC)	within 15 minutes pre-dose and at specified time points up to 24 hours post-dose
Terminal elimination half-life (t½)	within 15 minutes pre-dose and at specified time points up to 24 hours post-dose

Trial Locations

Locations (2)

Site 002; 🇺🇸 Dallas, Texas, United States

Site 001; 🇺🇸 Daytona Beach, Florida, United States